Rishi Raj, MD
Endocrinology, Diabetes & Metabolism · Pikeville, KYNPI 1770965683
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,741 of the $5,665 with a category attached, or 83.7%. It is spread thinly across 30 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,399 and has fallen 86.7% since, to $187 in 2025.
Across 270 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$750
- Novo Nordisk$695
- Boehringer Ingelheim$580
- Sanofi-aventis U.S. LLC$518
- Abbott$415
- AbbVie$307
- plus $2K from 24 others
What the payments were for
- Grants$75013%
- Food & beverage$4,74184%
- Education$1733%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 1 | $750 |
| Novo Nordisk | 34 | $695 |
| Boehringer Ingelheim | 41 | $580 |
| Sanofi-aventis U.S. LLC | 33 | $518 |
| Abbott | 28 | $415 |
| AbbVie | 5 | $307 |
| Lilly USA, LLC | 25 | $305 |
| Corcept Therapeutics | 17 | $300 |
| Amgen | 18 | $280 |
| AstraZeneca(2 entities) | 10 | $243 |
| Gilead | 17 | $240 |
| Medtronic | 4 | $150 |
| Dexcom, Inc. | 4 | $133 |
| Merck | 5 | $110 |
| Mallinckrodt Hospital Products Inc. | 5 | $101 |
| Johnson & Johnson | 1 | $91 |
| Melinta Therapeutics, LLC | 5 | $85 |
| Kyowa Kirin, Inc. | 3 | $55 |
| Seagen Inc. | 1 | $50 |
| Incyte Corporation | 1 | $49 |
| Jazz Pharmaceuticals Inc. | 1 | $41 |
| Boston Scientific | 2 | $39 |
| Ultragenyx Pharmaceutical Inc. | 2 | $30 |
| La Jolla Pharmaceutical Company | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Shionogi Inc | 1 | $14 |
| UCB, Inc. | 1 | $14 |
| Biogen | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| GRT US Holding, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$125
How this compares
$5,665 in reported general payments places this provider in the 60th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CrysvitaBurosumab-Twza | 16 | $832,742 |
| OzempicSemaglutide | 330 | $352,527 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 110 | $177,056 |
| TrulicityDulaglutide | 98 | $112,253 |
| MounjaroTirzepatide | 79 | $93,846 |
| FarxigaDapagliflozin Propanediol | 76 | $84,156 |
| JardianceEmpagliflozin | 77 | $60,301 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 243 | $59,795 |
| ForteoTeriparatide | 14 | $50,623 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 34 | $38,315 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $30,043 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 68 | $28,245 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $23,697 |
| Humalog Kwikpen U-100Insulin Lispro | 56 | $14,169 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 20 | $12,801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Kyowa Kirin, Inc.Crysvita | $55 | $832,74216 claims |
| Novo NordiskOzempic, Novolog | $695 | $357,370352 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog | $305 | $265,125212 claims |
| AstraZenecaFarxiga | $243 | $84,15676 claims |
| Boehringer IngelheimJardiance | $580 | $60,30177 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $518 | $7,97614 claims |
| AbbVieSynthroid | $307 | $4,01947 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Pikeville
- Marvin BishopPikeville$14K
- Bradley EilermanFlorence$1.3M
- Sergio Chang FigueroaMadisonville$1.2M
- Hisham AlrefaiLouisville$720K
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
- Yancey HolmesCovington$148K
- Moussa AlhajAshland$111K
- Mehdi PoorkayLouisville$81K
- Lyle MyersLexington$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.